Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-04
2009-11-03
Shiao, Rei-Tsang (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S138000
Reexamination Certificate
active
07612104
ABSTRACT:
The present invention comprises bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, their functional derivatives thereof as well as their physiologically acceptable salts and pharmaceutical compositions thereof that exhibit peroxisome proliferator activated receptor (PPAR) PPARdelta and PPARgamma agonist activity. The structure of the compounds of the invention are defined by Formula I below,wherein the various substituents are defined herein, including their physiologically acceptable salts. Processes for the compounds preparation are also disclosed. The compounds are suitable for the treatment of fatty acid metabolism and glucose utilization disorders, disorders relating to insulin resistance are involved as well as demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.
REFERENCES:
patent: 3565897 (1971-02-01), Heerdt et al.
patent: 5097669 (1992-03-01), Hargrove et al.
patent: 1277729 (2003-01-01), None
patent: WO 2005/005421 (2005-01-01), None
“Metabolic Syndrome.” American Heart Association. <http://www.americanheart.org/presenter.jhtml?identifier=4756> Accessed Mar. 30, 2009.
Grundy et al. “Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement.” Circulation 112 (2005), pp. 2735-2752.
Mathur, Ruchi. “Metabolic Syndrome.” MedicineNet.com. <http://www.medicinenet.com/metabolic—syndrome/article.htm> Accessed Mar. 31, 2009.
Rubenstrunk et al. “Safety issues and prospects for future generations of PPAR modulators.” Biochimica et Biophysica Acts 1771 (2007) 1065-1081.
Glien Maike
Keil Stefanie
Matter Hans
Schoenafinger Karl
Urmann Matthias
Fierro Alicia L
Lin Jiang
Sanofi-Aventis
Shiao Rei-Tsang
LandOfFree
Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4058127